Holger Kroenig, MD, Pharm D
About Holger Kroenig, MD, Pharm D
Holger Kroenig, MD, Pharm D, is the Senior Medical Director Oncology at Bristol Myers Squibb in Germany, with extensive experience in oncology and hematology.
Current Role at Bristol Myers Squibb
Holger Kroenig, MD, Pharm D, serves as the Senior Medical Director Oncology at Bristol Myers Squibb (BMS) in Germany. Based in the Metropolregion München, Dr. Kroenig also acts as the Project Lead for early asset development in major markets globally. His role primarily focuses on oncology, where he leads initiatives in clinical research, medical monitoring, and strategic development.
Previous Experience at Bristol Myers Squibb
From 2016 to 2021, Holger Kroenig held the position of Disease Area Head and Medical Director for Oncology & Hematology at Bristol Myers Squibb. During his five-year tenure in München und Umgebung, he led a team of over 50 members and was responsible for overseeing various projects and initiatives within the oncology and hematology fields.
Tenure at Gilead Sciences
In 2014, Holger Kroenig joined Gilead Sciences as an Associate Director in Oncology, Medical Affairs. He held this position for one year in the Munich Area, Germany. His responsibilities included overseeing oncology-related medical affairs and contributing to business development initiatives within the oncology sector.
Medical Director Experience at PRA International
Between 2012 and 2014, Holger Kroenig worked at PRA International as a Medical Director in Hematology/Oncology within the Medical Affairs department. Located in Munich, Germany, Dr. Kroenig focused on medical monitoring and clinical research, contributing significantly to the organization’s research and development efforts.
Educational Background
Holger Kroenig completed his Doctor of Medicine (MD) from Ludwig-Maximilians Universität München, attending medical school from 1998 to 2004. He also earned a PharmD degree following a state examination in Pharmacy from the university’s Faculty of Chemistry and Pharmacy, where he studied from 1996 to 2000. Additionally, he obtained Board Certification in Hematology/Oncology from Bayerische Landesärztekammer.